Anticancer agent 231

CAS: 128519-30-2 F: C23H22ClN3 W: 375.89

Anticancer agent 231 (Compound P5) is a tyrosine protein kinase inhibitor with a IC50 value of 3.95 μM. Anticancer agen

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Anticancer agent 231 (Compound P5) is a tyrosine protein kinase inhibitor with a IC50 value of 3.95 μM. Anticancer agent 231 inhibits the cell viability, cell proliferation, cell migration and cancer dryness of triple negative breast cancer (TNBC) cells by targeting EGFR-ERK 1/2 signaling pathway, and is expected to play an important role in the field of TNBC disease therapy[1].
Invitro	Anticancer agent 231 (化合物 P5) 具有良好的细胞毒性并抑制 TNBC 细胞的生存能力[1]。Anticancer agent 231 (化合物 P5) (1, 2, 4 μM, 14 天; 1, 2, 4 μM, 8 天) 减弱 Hs578T 细胞和 MDA MB 231 细胞的增殖能力[1]。Anticancer agent 231 (化合物 P5) (1, 2, 4 μM, 12 h) 减弱 Hs578T 细胞的迁移能力[1]。Anticancer agent 231 (化合物 P5) (1, 2 μM) 抑制肿瘤干性并增强 TNBC 细胞对紫杉醇的敏感性[1]。Anticancer agent 231 (化合物 P5) (1, 2, 4 μM; 5, 10, 20 μM)通过靶向 EGFR-ERK 1/2 轴来抑制 TNBC 细胞[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Anticancer agent 231 相关抗体: Cell Line:
CAS	128519-30-2
Formula	C23H22ClN3
Molar Mass	375.89
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Satriyo PB, et al. N-phenyl pyrazoline derivative inhibits cell aggressiveness and enhances paclitaxel sensitivity of triple negative breast cancer cells. Sci Rep. 2024 Jun 8;14(1):13200.